Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies
Go back to Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies| CACI INTERNATIONAL CLA (NASDAQ: CAI) | Delayed: 17.81 -0.49 (2.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.30 | 52 Week High | $11.53 | |||
| Open | $18.03 | 52 Week Low | $4.83 | |||
| Day High | $18.38 | P/E | 6.04 | |||
| Day Low | $17.60 | EPS | $2.95 | |||
| Volume | 2,611,053 | |||||
